{
    "clinical_study": {
        "@rank": "47133", 
        "brief_summary": {
            "textblock": "RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing\n      so they stop growing or die.\n\n      PURPOSE: This phase II trial is studying how well gemcitabine and cisplatin work in treating\n      patients with metastatic kidney cancer."
        }, 
        "brief_title": "Gemcitabine Plus Cisplatin in Treating Patients With Metastatic Kidney Cancer", 
        "completion_date": {
            "#text": "April 2006", 
            "@type": "Actual"
        }, 
        "condition": "Kidney Cancer", 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma, Renal Cell", 
                "Kidney Neoplasms"
            ]
        }, 
        "detailed_description": {
            "textblock": "OBJECTIVES:\n\n        -  Assess the response rate of patients with metastatic renal cell carcinoma treated with\n           gemcitabine and cisplatin.\n\n        -  Assess toxicity of this regimen in these patients.\n\n      OUTLINE: Patients receive gemcitabine IV over 30 minutes on days 1, 8, and 15 and cisplatin\n      IV over 60 minutes on day 15. Courses repeat every 28 days in the absence of disease\n      progression or unacceptable toxicity.\n\n      Patients are followed every 4 months.\n\n      PROJECTED ACCRUAL: Approximately 29-38 patients will be accrued for this study."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "DISEASE CHARACTERISTICS:\n\n          -  Histologically proven metastatic renal cell carcinoma\n\n          -  No brain metastases\n\n        PATIENT CHARACTERISTICS:\n\n        Age:\n\n          -  Over 18\n\n        Performance status:\n\n          -  ECOG 0-2\n\n        Life expectancy:\n\n          -  At least 12 weeks\n\n        Hematopoietic:\n\n          -  WBC at least 3,500/mm^3\n\n          -  Hematocrit at least 30%\n\n          -  Platelet count at least 100,000/mm^3\n\n        Hepatic:\n\n          -  Bilirubin no greater than 2.0 mg/dL\n\n          -  AST and ALT no greater than 1.5 times upper limit of normal\n\n        Renal:\n\n          -  Creatinine no greater than 1.5 mg/dL OR\n\n          -  Creatinine clearance at least 60 mL/min\n\n        Cardiovascular:\n\n          -  No uncontrolled hypertension\n\n          -  No myocardial infarction within the past 8 weeks\n\n        Other:\n\n          -  Not pregnant or nursing\n\n          -  Fertile patients must use effective contraception\n\n          -  No other prior malignancy within the past 5 years except nonmelanomatous skin cancer,\n             carcinoma in situ of cervix, prostate intraepithelial neoplasia, or superficial\n             bladder cancer\n\n          -  No significant psychiatric disease\n\n          -  No active infection\n\n        PRIOR CONCURRENT THERAPY:\n\n        Biologic therapy:\n\n          -  No more than 2 prior biologic response modifier regimens\n\n          -  No concurrent biologic therapy\n\n        Chemotherapy:\n\n          -  No prior chemotherapy\n\n          -  No other concurrent chemotherapy\n\n        Endocrine therapy:\n\n          -  Not specified\n\n        Radiotherapy:\n\n          -  Prior radiotherapy allowed if measurable disease is outside radiation port\n\n          -  At least 28 days since prior radiotherapy\n\n          -  No concurrent radiotherapy\n\n        Surgery:\n\n          -  Prior surgery allowed"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "32", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "November 1, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00003928", 
            "org_study_id": "CWRU3897", 
            "secondary_id": [
                "P30CA043703", 
                "CWRU-3897", 
                "NCI-G99-1530"
            ]
        }, 
        "intervention": [
            {
                "description": "Cisplatin IV over 60 minutes on day 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.", 
                "intervention_name": "cisplatin", 
                "intervention_type": "Drug"
            }, 
            {
                "description": "Gemcitabine IV over 30 minutes on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.", 
                "intervention_name": "gemcitabine hydrochloride", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Gemcitabine", 
                "Cisplatin"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "stage IV renal cell cancer", 
            "recurrent renal cell cancer"
        ], 
        "lastchanged_date": "June 9, 2010", 
        "link": {
            "description": "Clinical trial summary from the National Cancer Institute's PDQ\u00ae database", 
            "url": "http://cancer.gov/clinicaltrials/CWRU-3897"
        }, 
        "location": {
            "facility": {
                "address": {
                    "city": "Cleveland", 
                    "country": "United States", 
                    "state": "Ohio", 
                    "zip": "44106-5065"
                }, 
                "name": "Ireland Cancer Center at University Hospitals Case Medical Center, Case Comprehensive Cancer Center"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase II Study Utilizing Gemcitabine and Cisplatinum in Patients With Renal Cell Carcinoma", 
        "overall_official": {
            "affiliation": "Ireland Cancer Center at University Hospitals Case Medical Center, Case Comprehensive Cancer Center", 
            "last_name": "Scot C. Remick, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Federal Government", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "February 2005", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Assess the response rate of patients with  metastatic renal cell carcinoma treated with gemcitabine and cisplatin.", 
            "safety_issue": "No", 
            "time_frame": "Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00003928"
        }, 
        "responsible_party": {
            "name_title": "Scot C. Remick, MD", 
            "organization": "Ireland Cancer Center at University Hospitals Case Medical Center, Case Comprehensive Cancer Center"
        }, 
        "source": "Case Comprehensive Cancer Center", 
        "sponsors": {
            "collaborator": {
                "agency": "National Cancer Institute (NCI)", 
                "agency_class": "NIH"
            }, 
            "lead_sponsor": {
                "agency": "Case Comprehensive Cancer Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 1999", 
        "study_design": "Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "June 2010"
    }, 
    "geocoordinates": {
        "Ireland Cancer Center at University Hospitals Case Medical Center, Case Comprehensive Cancer Center": "41.499 -81.695"
    }
}